Journal article icon

Journal article

Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial

Abstract:

Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero. Methods: We did this superiority, placebo-controlled randomised trial in 19 fetal medicine units in the UK. ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/S2352-4642(17)30173-6

Authors


Cornforth, C More by this author
Jackson, R More by this author
Harrold, J More by this author
Turner, MA More by this author
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
Lancet Child and Adolescent Health Journal website
Volume:
2
Issue:
2
Pages:
93-102
Publication date:
2017-12-07
DOI:
ISSN:
2352-4642
Pubs id:
pubs:825571
URN:
uri:b17bd6ff-15d5-4157-8798-2e16032af020
UUID:
uuid:b17bd6ff-15d5-4157-8798-2e16032af020
Local pid:
pubs:825571

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP